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1. Introduction
Carvedilol,  or  (±)-1-9H-(carbazol-4-yloxy)-
3-[[2-(2-methoxyphenoxy)  ethyl]amino]-2-propanol, 
is an antihypertensive agent with β- and α1-adrenergic 
receptor  blocking  activities.1-3 Carvedilol  has  much 
greater antioxidant activity than other commonly-used 
β  –blockers.4-5 It  has  been  prescribed  as  an 
antihypertensive agent and an angina agent6-7 and for 
treatment  of  congestive  heart  failure.8  High-
performance  liquid  chromatography  (HPLC)  with 
fluorescence  detector,9-14 mass  spectrometer15-16  or 
electrochemical  detection17  has  been  used  for  the 
analysis of carvedilol and its enantiomers in biological 
samples.  Determination  of  cavedilol  by  capillary 
electrophoresis  has  also  been  reported.17,18  HPLC 
with  UV  detector19-21  and  differential  pulse 
voltammetric  determination22  have  been  also  used. 
There  have  been  few  published  articles  on  the 
evaluation  of  carvedilol  in  pharmaceutical 
formulations.  In  this  study,  efforts  were  made  for 
developing  a  simple,  easy and  cost  effective  HPLC 
method  using  UV  detector  and  a  readily  available 
solvent. The method was optimized and validated as 
per the ICH guidelines.23 
2. Material and Methods
2.1. Active drug and reagents: Carvedilol was kindly 
supplied by Incepta Pharmaceutical Ltd (Bangladesh) 
and was used as the reference standard. All chemicals 
and  reagents  were  of  analytical  or  pharmaceutical 
grade.
2.2.  Instrumentation  and  chromatographic  
condition:  An  integrated  high  performance  liquid 
chromatography system (Shimadzu) was used for this 
experiment. A C18 L1, pH resistant  (4.5 mm x 250 
nm: 5µm) column (Luna, Phenomenex) was used. The 
detector was set at 240 nm and the run time was 15 
minutes  at  a  flow  rate  of  1  ml/  minute  at  room 
temperature.
2.3. Pharmaceutical formulation: Commercial 
tablets (Effient) were procuredfrom the local market.
2.4. Method development: Buffer (Potassium Dihydro 
Phosphate was dissolved., pH was adjusted to 2 with 
the help of phosphoric acid) in different proportions 
were tried and finally buffer and acetonitrile (65: 35 
v/v)  was  selected  as  an  appropriate  mobile  phase 
which  gave  good  resolution  and  acceptable  system 
suitability parameters.
2.5 Linearity  Study:  Accurately  weighed  25mg 
Carvedilol,  was transferred  into a  100ml volumetric 
flask. An amount of mobile phase (50ml) was added; 
it was then shaken for 5-10 minutes and diluted to the 
100ml mark  with  same solvent  to  prepared  Cs.  For 
linearity study, five aliquots in the range of 0.2 ml to 
1.4 ml of Cs were taken and diluted to 10 ml with 
mobile phase to obtain different concentrations within 
the range 5µg/ml to 35µg/ml and used for the linearity 
calibration plot.
2.6  Precision  Study:  Accurately  weighed  tablet 
powder,  equivalent  to  25mg  Carvedilol,  was 
transferred into a 100ml volumetric flask. An amount 
of mobile phase (50ml) was added; it was then shaken 
for 5-10 minutes and diluted to the 100ml mark with 
same  solvent.  It  was  then  filtered  and  was  further 
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diluted  0.8ml,  1ml  and  1.2ml  to  10ml to  obtain  20 
µg/ml,  25  µg/ml,  30  µg/ml,  respectively.  Triplicate 
absorbance measurements of each were made and the 
mean, standard deviation and RSD were calculated.
The selected concentrations for the intra-day 
precision study were again analyzed the following day 
and  the  mean,  standard  deviation  and  RSD  were 
calculated.
2.7 Accuracy Study: This study was carried out using 
reformulated granules containing pure Carvedilol, and 
common  excipients  including  maize  starch,  sodium 
starch glycol ate, avicel PH 101, magnesium stearate 
and purified talc. 50mg, granules was then transferred 
respectively  into  three  100ml  volumetric  flasks  and 
diluted to the 100ml mark with mobile phase and then 
filtered.  Same dilution  pattern  as  reference  solution 
was  followed  to  obtain  three  concentrations,  80%, 
100% and  120% of  reference  solution  respectively. 
The solutions were analyzed then for  the content of 
Carvedilol using the proposed method with a standard 
solution 15µg/ml of pure Carvedilol. All analysis was 
carried out in triplicate.
2.8 Specificity in the Presence of Excipients:  This 
test  was  carried  out  using  only  excipients.  Placebo 
granules devoid of the pure carvedilol were prepared, 
their  absorbance  reading  at  240nm  taken  and 
compared with both that of the blank and that obtained 
for the recovery study.
Limit of detection (LOD) and Limit of quantification  
(LOQ): Limit  of  detection  (LOD)  and  Limit  of 
quantification  (LOQ)  for  the  assay  were  calculated 
using the following equations. 24
LOD = 3.3 ×S0/ b and LOQ = 10 ×S0/ b 
Where  S0  and b are  the  standard  deviation 
and the slope of the calibration line.
2.9.  Assay  of  content  of  Carvedilol  in  selected 
marketed  brands:  This  was  carried  out  using  the 
developed and validated method as follows-
Sample  Preparation:  10  tablets  is  weighted  and 
crushed  and  from  that  accurately  weighed  tablet 
powder,  equivalent  to  25mg  Carvedilol,  was 
transferred into a 100ml volumetric flask. An amount 
of mobile phase (50ml) was added; it was then shaken 
for 5-10 minutes and diluted to the 100ml mark with 
same  solvent.  It  was  then  filtered  and  was  further 
diluted 1ml to obtain 25 µg/ml. Triplicate absorbance 
measurements  of  each  were  made  and  the  mean, 
standard deviation and RSD were calculated.
3.8.9 Reference  Standard Preparation:  1ml of  Cs 
was diluted to 10ml of mobile phase to obtain a 25 
µg/ml of  Carvedilol reference standard solution. The 
absorbance  of  the  sample  preparation  and  reference 
standard solution were taken using MeOH as blank. 
The content of carvedilol in the marketed brands was 
determined using the following equation-
Content  of  Carvedilol (%)  per  tablet  =  (As/Ast)  × 
(Wst/100 × 1/10) × (100/Ws × 10/1) × W × P/100
Where,
As =area of generic sample solution,
Ast = area of reference Carvedilol standard solution,
Wst = weight of reference Carvedilol powder (mg)
Ws = weight of generic powder sample (mg)
W = average weight of tablet (mg)
P = potency of standard Carvedilol
Statistical  analysis: Where  applicable,  results  were  
expressed as mean ± SD and analyzed statistically.
3. Results and Discussion
The linearity parameter (Table 1 & Figure 1) 
and  the  corresponding  regression  data,  indicated 
excellent  linear  relationship  (R2  =  0.998)  over  the 
working  concentration  range  (5-35  µg/ml).  Table  2 
and Table 3 presents respectively the intra-and inter-
day precision of the new method, confirming adequate 
sample  stability  and  method reliability  over  a  24  h 
period.  This  is  because  for  the  three  selected 
concentrations within the linearity range, the observed 
RSDs were all < 2.0 %. The result of Accuracy (Table 
4)  was  within  the  range  of  ICH  guideline.  The  % 
accuracy indicated non-interference from excipients of 
formulation.  The  results  of  analysis  of  5  marketed 
brands were good and shown in Table 5. The limit of 
detection  (LOD)  and Limit  of  quantification  (LOQ) 
were  calculated  as  35  µg/ml  and  108  µg/ml 
respectively.
Table 1: Linear regression data for calibration 
curves
Parameter Carvedilol
Linearity range (μg/ml) 5-35 µg/ml
Correlation coefficient 0.998
Slope 14625
Intercept 14778
Figure 1: Calibration curve for cavedilol
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Table 2: Intra-day precision study of Carvedilo
Intra-day Precision study( n=3 replicates)
Declared 
Conc. (µg/ml)
Calculated concentration 
(µg/ml) Mean ± SD RSD Average Potency 
1 2 3
20 19.8 19.9 19.7 19.8±0.1 0.50% 99.00%
25 25.1 24.8 24.9 24.9±0.15 0.61% 99.73%
30 29.8 29.7 29.9 29.8±0.1 0.33% 99.33%
Table 3: Inter-day precision study of Carvedilo
Inter-day Precision study( n=3 replicates)
Declared 
Conc. (µg/ml)
Calculated 
concentration 
(µg/ml) Mean ± SD RSD Average Potency 
1 2 3
20 19.8 19.9 19.7 19.8±0.1 0.50% 99.00%
25 25.1 24.8 24.9 24.9±0.15 0.61% 99.73%
30 29.8 29.7 29.6 29.7±0.1 0.33% 99.00%
Table 4: Accuracy study of Carvedilol
Accuracy study ( n=3)
Dosage form
Labeled 
claim
Amount 
added (%) Area of peak % Recovered
Pre formulated 
granules
25 mg
80 294696±0.28 98.08%
100 350485±0.16 99.02%
120 421111±0.25 99.91%
Table 5: Assay of Carvedilol in marketed tablets
Assay of Carvedilol in marketed tablets( n=3)
Formulation Labeled claim Amount found ±SD Assay RSD
Brand 1 25 mg 24.76±0.25 99.04 1.00
Brand 2 25 mg 24.56±0.89 98.24 3.60
Brand 3 25 mg 24.91±0.03 99.64 0.10
Brand 4 25 mg 24.38±0.78 97.52 3.10
Brand 5 25 mg 25.1±0.23 100.4 0.91
Table 5: Summary of validation parameters
Parameter Carvedilol
Intraday precision <2%
Retention time (min) 15min
Theoretical plates 2500
Tailing factor 1.2
4. Conclusion
The proposed method is simple and do not 
involve laborious time-consuming sample preparation. 
The results and the statistical parameters demonstrate 
that  the  proposed  HPLC  method  is  simple,  rapid, 
selective,  accurate,  precise  and  highly  sensitive. 
Therefore,  it  can  be  used  for  the  determination  of 
Carvedilol  either  in  bulk  or  in  their  corresponding 
dosage forms. So this HPLC method can be used in 
the quality control department. 
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